Large frontline trials of conventional dose therapy in MCL
| Phase . | Chemotherapy . | N . | Age (median), years . | OR (CR), % . | Median PFS, months . | OS . | Reference . |
|---|---|---|---|---|---|---|---|
| 3 (Randomized) | FC vs FCR | 370 | 66 | 68 (40) vs 74 (53) | 14.9 vs 29.8 | Median 37 vs 44.5 months | Rule et al4 |
| 3 (Randomized) | R-CHOP vs R-FC | 485 | 70 | Postinduction 86 (34) vs 78 (40) | 28 (TTF) vs 26 (TTF) | Postmaintenance 4 years 62% vs 4 years 47% | Kluin-Nelemans et al22 |
| 3 (Randomized) | R- CHOP vs R-B | 94 | 70 | 91 (30) vs 93 (40) | 22 vs 35 | NA | Rummel et al23 |
| 3 (Randomized) | R-CHOP/CVP vs R-B | 74 | 60 | 85 (27) vs 94 (50) | NA | NA | Flinn et al24 |
| 3 (Randomized) | R-CHOP vs VR-CAP | 244 | 61 | 89 (42) vs 92 (53) | 14.4 vs 24.7 | 4 years 54% vs 4 years 64% | Robak et al33 |
| 2 (Single arm) | R-BAC (AraC 500 mg/m2) | 57 | 71 | 96 (93) | 2 years PFS 83% | 2 years OS 91% | Visco et al26 |
| Phase . | Chemotherapy . | N . | Age (median), years . | OR (CR), % . | Median PFS, months . | OS . | Reference . |
|---|---|---|---|---|---|---|---|
| 3 (Randomized) | FC vs FCR | 370 | 66 | 68 (40) vs 74 (53) | 14.9 vs 29.8 | Median 37 vs 44.5 months | Rule et al4 |
| 3 (Randomized) | R-CHOP vs R-FC | 485 | 70 | Postinduction 86 (34) vs 78 (40) | 28 (TTF) vs 26 (TTF) | Postmaintenance 4 years 62% vs 4 years 47% | Kluin-Nelemans et al22 |
| 3 (Randomized) | R- CHOP vs R-B | 94 | 70 | 91 (30) vs 93 (40) | 22 vs 35 | NA | Rummel et al23 |
| 3 (Randomized) | R-CHOP/CVP vs R-B | 74 | 60 | 85 (27) vs 94 (50) | NA | NA | Flinn et al24 |
| 3 (Randomized) | R-CHOP vs VR-CAP | 244 | 61 | 89 (42) vs 92 (53) | 14.4 vs 24.7 | 4 years 54% vs 4 years 64% | Robak et al33 |
| 2 (Single arm) | R-BAC (AraC 500 mg/m2) | 57 | 71 | 96 (93) | 2 years PFS 83% | 2 years OS 91% | Visco et al26 |
CVP, cyclophosphamide, vincristine, and prednisolone; FCR, fludarabine, cyclophosphamide, and rituximab; N, number; NA, not available; R-B, rituximab and bendamustine; R-BAC, rituximab, bendamustine, and cytarabine; R-FC, rituximab, fludarabine, and cyclophosphamide; TTF, time to treatment failure.